Christopher P. Crum, MD Professor of Pathology, Harvard Medical School Division of Women’s and Perinatal Pathology Department of Pathology Brigham and Women’s Hospital Objectives: - Describe two evolutionary pathways for serous tubal intraepithelial carcinoma (STIC).
- Describe two possible molecular events leading to rapidly developing high-grade serous carcinoma.
- Describe two potential opportunities for preventing high-grade serous carcinoma.
Speaker disclosures: Dr. Christopher Crum has NOT had any financial relationships with any ineligible entities within the past 24 months.Why Attend? In the past 22 years, our understanding of the pathogenesis of extra-uterine high grade serous carcinoma has undergone a revolution, fueled largely by the attention to prophylactic salpingo-oophorectomy specimens from asymptomatic women with germ-line BRCA1 and BRCA2 mutations. The discovery of a serous carcinogenic sequence in the distal fallopian tube has shifted attention to the role of the fimbria in both early detection and prevention. Ultimately, what has emerged is an appreciation of two different trajectories of HGSC development, one delayed, often following the discovery of significant precursors (STIC) by several years and another, characterized by the seemingly sudden emergence of widespread disease. This presentation will address the possible explanations for these two trajectories from the pathologic and molecular perspective and, in the context of emerging follow-up data, outline two different opportunities for preventing and lowering the mortality rate for this most lethal form of "ovarian" cancer. Meeting ID: 983 8715 9855 Passcode: PATHGR You must sign-in on the following form to receive CME credit. Sign-in online: https://forms.gle/W2oE8d3MYbnyTDe58 Planning Committee Disclosure: The following members have not had any financial relationships with any ineligible entities in the past 24 months: Drs. Rebecca Alvarez, Eleanor Chen, Austin Green, Jose Mantilla, Isaac Miller, Elizabeth Parker, Maria Tretiakova, and Larry True. The following members disclose financial relations with ineligible entities within the past 24 months: Dr Shreeram Akilesh GoldfinchBio, Inc. (sponsored research) and NanoString, Inc. (sponsored travel); and Dr. Haodong Xu PathomIQ (consultant). All relevant financial relationships listed have been mitigated. Grant Acknowledgment: None
CME Accreditation statement: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Washington School of Medicine designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. (Each session is 1.0 credit) |